BGB-43395 drug page Clinical trials

Trials with BGB-43395

Every colorectal cancer trial that includes this drug. Those looking for patients come first.

2Trials
1Recruiting
11Countries
502Planned patients

Showing 1–2 of 2

BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Recruiting Phase 1 399 patients NCT06120283

This is a dose escalation and dose expansion study to compare how well BGB-43395, a selective cyclin-dependent kinase 4 (CDK4) inhibitor, works as monotherapy or in combination with fulvestrant, letrozole, or elacestrant in participants wi…

United States, Australia, Brazil, China and 6 more Dec 2023 – Nov 2028 Interventional
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
Ongoing, not recruiting Phase 1 103 patients NCT06257264

This study is a first-in-human (FIH), Phase 1a/1b study of BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of BG-68501…

United States, Australia, China, Israel and 2 more Mar 2024 – Aug 2026 Interventional
Combined with: BG-68501Fulvestrant

Where the recruiting trials are